Sunday 18 October 2026
Export RZLT’s income statement to Excel — free account
Rezolute, Inc.
RZLT Healthcare Biotechnology
In the quarter to June 2026, EPS grew 23.1% and free cash flow grew 40.2%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
3.58
0.32
−8.21%
Follow RZLT
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (59.04%) | (81.73%) | (74.02%) | (59.23%) |
+8 more TTM periods Free account |
|
| (53.82%) | (74.01%) | (67.21%) | (54.73%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(78.26%) | (71.23%) | (67.04%) | (53.39%) | |
Free Cash Flow per Share |
(0.62) | (0.71) | (0.74) | (0.68) | |
Free Cash Flow |
(64.63) | (73.48) | (77.15) | (70.49) | |
| Other line items | |||||
Cash ROIC |
(31.00%) | (30.99%) | (29.57%) | (23.55%) | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Operating CF/Net income |
0.83 | 0.90 | 0.92 | 0.91 | |
Depreciation/Fixed assets |
(58.98) | (46.88) | (40.68) | (36.37) | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.62) | (0.71) | (0.74) | (0.68) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates · fundamentals updated 2 Oct 2026